Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal

L Epprecht, S R Schreglmann, O Goetze, D Woitalla, C R Baumann, D Waldvogel, L Epprecht, S R Schreglmann, O Goetze, D Woitalla, C R Baumann, D Waldvogel

Abstract

Delayed gastric emptying (GE) is a frequent non-motor feature in Parkinson´s disease (PD). This prospective study (clinicaltrials.gov Identifier NCT01518751) investigated GE and visceral perception in early motor phase PD patients in comparison to age-matched and younger controls. In addition, the effect of Levodopa on GE was assessed in healthy aged controls. 16 PD patients (Hoehn & Yahr 2), 11 sex-/age-matched Ctrl1 and 10 young, male Ctrl2 subjects were subjected to a high caloric (428 kcal) (13)C-Sodium Octanoate breath test strictly OFF dopaminergic medication. Visceral appetite sensation was monitored using visual analogue scales (VAS). GE was similarly studied in 7 controls ON/OFF oral Levodopa. GE was not altered in PD patients compared to age-/sex-matched and younger controls (p = 0.76). Subjective appetite perception was not altered in the PD group in comparison to Ctrl1, but was significantly higher in Ctrl2 subjects (p = 0.02). 100 mg oral Levodopa/25 mg Benserazide significantly slowed GE by 18% among healthy controls (p = 0.04). In early motor stage PD OFF dopaminergic medication, there was no GE slowing after a high caloric test meal. Levodopa, however, caused a robust GE slowing in healthy aged individuals. Our data indicate that clinically relevant GE slowing in early PD is related to the iatrogenic effect of dopamine treatment. Subjective appetite perception is not affected in this disease stage. This data add to the understanding of gastrointestinal symptoms in early motor stage PD and highlight the influence of dopaminergic medication.

References

    1. Mov Disord. 2001 Nov;16(6):1041-7
    1. Gut. 1995 Feb;36(2):183-8
    1. Neurodegener Dis Manag. 2014;4(4):309-16
    1. Aliment Pharmacol Ther. 2011 Apr;33(8):880-94
    1. J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25
    1. Lancet Neurol. 2003 Feb;2(2):107-16
    1. Aliment Pharmacol Ther. 2007 Feb 15;25(4):477-86
    1. J Neurol. 2011 Mar;258(3):421-6
    1. Gastroenterology. 1993 Jun;104(6):1640-7
    1. PLoS One. 2013;8(1):e53290
    1. Scand J Gastroenterol. 2000 Aug;35(8):814-8
    1. Aliment Pharmacol Ther. 2003 Jul 1;18(1):141-50
    1. Parkinsonism Relat Disord. 2012 Jun;18(5):433-40
    1. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):193-203
    1. J Neurol. 2005 Sep;252(9):1055-9
    1. Neurosci Lett. 2005 Mar 3;375(3):170-3
    1. J Neurol. 2009 Dec;256(12):1972-6
    1. J Neurol. 2011 Jun;258(6):982-90
    1. J Neurol. 2012 Dec;259(12):2621-31
    1. Mov Disord. 2010 Nov 15;25(15):2493-500
    1. Eur J Clin Pharmacol. 1992;42(4):409-12
    1. Neurology. 1988 Mar;38(3):419-21
    1. Acta Neuropathol. 2012 Nov;124(5):665-80
    1. Clin Neuropharmacol. 2006 Mar-Apr;29(2):61-7
    1. Mov Disord. 2011 Dec;26(14 ):2559-63
    1. Appetite. 2015 Jan;84:204-11
    1. Mov Disord. 2013 Apr;28(4):529-33
    1. J Clin Gastroenterol. 2009 Aug;43(7):639-43
    1. Best Pract Res Clin Anaesthesiol. 2006 Sep;20(3):397-407
    1. Gut. 1980 Sep;21(9):753-9
    1. Neurogastroenterol Motil. 2006 May;18(5):369-75
    1. Scand J Gastroenterol. 1995 Sep;30(9):880-5
    1. Nat Rev Endocrinol. 2013 Oct;9(10):584-97
    1. J Hum Nutr Diet. 2012 Feb;25(1):3-15
    1. Neurosci Lett. 2006 Mar 20;396(1):67-72
    1. J Clin Endocrinol Metab. 2009 Apr;94(4):1379-85
    1. Mov Disord. 2010 Nov 15;25(15):2649-53
    1. Mov Disord. 2014 Jan;29(1):23-32
    1. Neurology. 1996 Apr;46(4):1051-4
    1. Neurology. 2007 Jul 24;69(4):333-41
    1. Clin Pharmacol Ther. 1980 Mar;27(3):414-20
    1. J Physiol. 1997 Jan 15;498 ( Pt 2):553-9
    1. Metabolism. 2010 Apr;59(4):502-11
    1. Br J Clin Pharmacol. 1990 Jan;29(1):47-53
    1. J Neurol Sci. 2012 Aug 15;319(1-2):86-8
    1. Mov Disord. 2005;20 Suppl 11:S23-9
    1. Eur J Clin Nutr. 1992 Dec;46(12 ):879-84
    1. Neurogastroenterol Motil. 2012 May;24(5):e235-45

Source: PubMed

3
Tilaa